An attractive therapeutic target, mTOR pathway, in ALK+ anaplastic large cell lymphoma

Jeong Hee Cho, Francisco Vega, L. Jeffrey Medeiros

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase and a key regulator of cell growth and proliferation. Persistent activation of the mTOR pathway is a common event in several human tumors. Rapamycin, a macrolide antibiotic, inhibits the mTOR pathway and derivatives of rapamycin are currently being investigated as promising therapeutic agents in several cancers. Recent in vitro studies, including the report by Marzec et al discussed in this commentary, have reported activation of the mTOR pathway in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). ALK+ ALCL is a distinctive type of T/null-cell non-Hodgkin lymphoma characterized by the presence of chromosomal translocations involving the ALK gene, the most frequent being the t(2;5)(p23;q35). Marzec et al and others have shown that inhibition of mTOR pathway induces cell cycle arrest and apoptosis in ALK+ ALCL, thereby establishing rapamycin or, more likely, its derivatives as potential effective therapeutic agents. In addition, Marzec et al provide new insights by demonstrating that nucleophosmin-ALK induces activation of the mTOR pathway via the mitogen-induced extracellular kinase/extracellular signal-regulated kinase signaling pathway, in addition to the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway. Furthermore, a combination of an mTOR inhibitor with an inhibitor of the upstream mitogen-induced extracellular kinase/extracellular signal-regulated kinase pathway was more effective at inhibiting ALK+ ALCL cell proliferation than either inhibitor alone. In conclusion, there is growing evidence that the mTOR pathway is activated in ALK+ ALCL and that this pathway can be targeted as part of combination chemotherapy in patients with these lymphomas.

Original languageEnglish
Pages (from-to)105-112
Number of pages8
JournalAdvances in Anatomic Pathology
Volume15
Issue number2
DOIs
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

Anaplastic Large-Cell Lymphoma
Sirolimus
Therapeutics
Extracellular Signal-Regulated MAP Kinases
Mitogens
anaplastic lymphoma kinase
Phosphotransferases
Cell Proliferation
Phosphatidylinositol 3-Kinase
Null Lymphocytes
Proto-Oncogene Proteins c-akt
Genetic Translocation
T-Cell Lymphoma
Protein-Serine-Threonine Kinases
Macrolides
Cell Cycle Checkpoints
Combination Drug Therapy
Non-Hodgkin's Lymphoma
Lymphoma
Neoplasms

Keywords

  • Anaplastic large cell lymphoma
  • MEK/ERK
  • mTOR
  • NPM-ALK
  • PI3K/AKT

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Anatomy

Cite this

An attractive therapeutic target, mTOR pathway, in ALK+ anaplastic large cell lymphoma. / Cho, Jeong Hee; Vega, Francisco; Medeiros, L. Jeffrey.

In: Advances in Anatomic Pathology, Vol. 15, No. 2, 01.03.2008, p. 105-112.

Research output: Contribution to journalArticle

@article{7ca2107cacdf4689bd7876649ab91588,
title = "An attractive therapeutic target, mTOR pathway, in ALK+ anaplastic large cell lymphoma",
abstract = "Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase and a key regulator of cell growth and proliferation. Persistent activation of the mTOR pathway is a common event in several human tumors. Rapamycin, a macrolide antibiotic, inhibits the mTOR pathway and derivatives of rapamycin are currently being investigated as promising therapeutic agents in several cancers. Recent in vitro studies, including the report by Marzec et al discussed in this commentary, have reported activation of the mTOR pathway in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). ALK+ ALCL is a distinctive type of T/null-cell non-Hodgkin lymphoma characterized by the presence of chromosomal translocations involving the ALK gene, the most frequent being the t(2;5)(p23;q35). Marzec et al and others have shown that inhibition of mTOR pathway induces cell cycle arrest and apoptosis in ALK+ ALCL, thereby establishing rapamycin or, more likely, its derivatives as potential effective therapeutic agents. In addition, Marzec et al provide new insights by demonstrating that nucleophosmin-ALK induces activation of the mTOR pathway via the mitogen-induced extracellular kinase/extracellular signal-regulated kinase signaling pathway, in addition to the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway. Furthermore, a combination of an mTOR inhibitor with an inhibitor of the upstream mitogen-induced extracellular kinase/extracellular signal-regulated kinase pathway was more effective at inhibiting ALK+ ALCL cell proliferation than either inhibitor alone. In conclusion, there is growing evidence that the mTOR pathway is activated in ALK+ ALCL and that this pathway can be targeted as part of combination chemotherapy in patients with these lymphomas.",
keywords = "Anaplastic large cell lymphoma, MEK/ERK, mTOR, NPM-ALK, PI3K/AKT",
author = "Cho, {Jeong Hee} and Francisco Vega and Medeiros, {L. Jeffrey}",
year = "2008",
month = "3",
day = "1",
doi = "10.1097/PAP.0b013e318166139f",
language = "English",
volume = "15",
pages = "105--112",
journal = "Advances in Anatomic Pathology",
issn = "1072-4109",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - An attractive therapeutic target, mTOR pathway, in ALK+ anaplastic large cell lymphoma

AU - Cho, Jeong Hee

AU - Vega, Francisco

AU - Medeiros, L. Jeffrey

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase and a key regulator of cell growth and proliferation. Persistent activation of the mTOR pathway is a common event in several human tumors. Rapamycin, a macrolide antibiotic, inhibits the mTOR pathway and derivatives of rapamycin are currently being investigated as promising therapeutic agents in several cancers. Recent in vitro studies, including the report by Marzec et al discussed in this commentary, have reported activation of the mTOR pathway in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). ALK+ ALCL is a distinctive type of T/null-cell non-Hodgkin lymphoma characterized by the presence of chromosomal translocations involving the ALK gene, the most frequent being the t(2;5)(p23;q35). Marzec et al and others have shown that inhibition of mTOR pathway induces cell cycle arrest and apoptosis in ALK+ ALCL, thereby establishing rapamycin or, more likely, its derivatives as potential effective therapeutic agents. In addition, Marzec et al provide new insights by demonstrating that nucleophosmin-ALK induces activation of the mTOR pathway via the mitogen-induced extracellular kinase/extracellular signal-regulated kinase signaling pathway, in addition to the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway. Furthermore, a combination of an mTOR inhibitor with an inhibitor of the upstream mitogen-induced extracellular kinase/extracellular signal-regulated kinase pathway was more effective at inhibiting ALK+ ALCL cell proliferation than either inhibitor alone. In conclusion, there is growing evidence that the mTOR pathway is activated in ALK+ ALCL and that this pathway can be targeted as part of combination chemotherapy in patients with these lymphomas.

AB - Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase and a key regulator of cell growth and proliferation. Persistent activation of the mTOR pathway is a common event in several human tumors. Rapamycin, a macrolide antibiotic, inhibits the mTOR pathway and derivatives of rapamycin are currently being investigated as promising therapeutic agents in several cancers. Recent in vitro studies, including the report by Marzec et al discussed in this commentary, have reported activation of the mTOR pathway in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). ALK+ ALCL is a distinctive type of T/null-cell non-Hodgkin lymphoma characterized by the presence of chromosomal translocations involving the ALK gene, the most frequent being the t(2;5)(p23;q35). Marzec et al and others have shown that inhibition of mTOR pathway induces cell cycle arrest and apoptosis in ALK+ ALCL, thereby establishing rapamycin or, more likely, its derivatives as potential effective therapeutic agents. In addition, Marzec et al provide new insights by demonstrating that nucleophosmin-ALK induces activation of the mTOR pathway via the mitogen-induced extracellular kinase/extracellular signal-regulated kinase signaling pathway, in addition to the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway. Furthermore, a combination of an mTOR inhibitor with an inhibitor of the upstream mitogen-induced extracellular kinase/extracellular signal-regulated kinase pathway was more effective at inhibiting ALK+ ALCL cell proliferation than either inhibitor alone. In conclusion, there is growing evidence that the mTOR pathway is activated in ALK+ ALCL and that this pathway can be targeted as part of combination chemotherapy in patients with these lymphomas.

KW - Anaplastic large cell lymphoma

KW - MEK/ERK

KW - mTOR

KW - NPM-ALK

KW - PI3K/AKT

UR - http://www.scopus.com/inward/record.url?scp=65749091932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65749091932&partnerID=8YFLogxK

U2 - 10.1097/PAP.0b013e318166139f

DO - 10.1097/PAP.0b013e318166139f

M3 - Article

C2 - 18418091

AN - SCOPUS:65749091932

VL - 15

SP - 105

EP - 112

JO - Advances in Anatomic Pathology

JF - Advances in Anatomic Pathology

SN - 1072-4109

IS - 2

ER -